ALEMBIC PHARMA | DISHMAN PHARMA | ALEMBIC PHARMA/ DISHMAN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 17.5 | 25.1 | 69.8% | View Chart |
P/BV | x | 7.0 | 3.3 | 207.9% | View Chart |
Dividend Yield | % | 0.5 | 0.7 | 82.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
DISHMAN PHARMA Mar-16 |
ALEMBIC PHARMA/ DISHMAN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 374 | 177.4% | |
Low | Rs | 412 | 129 | 319.9% | |
Sales per share (Unadj.) | Rs | 208.7 | 197.8 | 105.5% | |
Earnings per share (Unadj.) | Rs | 31.0 | 21.2 | 146.2% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 34.7 | 106.9% | |
Dividends per share (Unadj.) | Rs | 5.50 | 2.00 | 275.0% | |
Dividend yield (eoy) | % | 1.0 | 0.8 | 128.6% | |
Book value per share (Unadj.) | Rs | 144.2 | 179.9 | 80.2% | |
Shares outstanding (eoy) | m | 188.52 | 80.69 | 233.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 1.3 | 202.7% | |
Avg P/E ratio | x | 17.4 | 11.9 | 146.3% | |
P/CF ratio (eoy) | x | 14.5 | 7.2 | 200.1% | |
Price / Book Value ratio | x | 3.7 | 1.4 | 266.8% | |
Dividend payout | % | 17.7 | 9.4 | 188.1% | |
Avg Mkt Cap | Rs m | 101,461 | 20,306 | 499.7% | |
No. of employees | `000 | NA | 0.8 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 5,355 | 139.4% | |
Avg. sales/employee | Rs Th | NM | 19,252.7 | - | |
Avg. wages/employee | Rs Th | NM | 6,459.5 | - | |
Avg. net profit/employee | Rs Th | NM | 2,064.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 15,961 | 246.5% | |
Other income | Rs m | 94 | 265 | 35.3% | |
Total revenues | Rs m | 39,441 | 16,226 | 243.1% | |
Gross profit | Rs m | 8,736 | 4,103 | 212.9% | |
Depreciation | Rs m | 1,152 | 1,091 | 105.7% | |
Interest | Rs m | 184 | 944 | 19.5% | |
Profit before tax | Rs m | 7,493 | 2,334 | 321.1% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 1 | -8,436.4% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 624 | 251.4% | |
Profit after tax | Rs m | 5,844 | 1,711 | 341.5% | |
Gross profit margin | % | 22.2 | 25.7 | 86.4% | |
Effective tax rate | % | 20.9 | 26.7 | 78.3% | |
Net profit margin | % | 14.9 | 10.7 | 138.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 11,018 | 177.7% | |
Current liabilities | Rs m | 14,896 | 9,517 | 156.5% | |
Net working cap to sales | % | 11.9 | 9.4 | 126.5% | |
Current ratio | x | 1.3 | 1.2 | 113.5% | |
Inventory Days | Days | 90 | 110 | 81.2% | |
Debtors Days | Days | 45 | 35 | 130.2% | |
Net fixed assets | Rs m | 27,097 | 16,304 | 166.2% | |
Share capital | Rs m | 377 | 161 | 233.6% | |
"Free" reserves | Rs m | 26,811 | 12,907 | 207.7% | |
Net worth | Rs m | 27,188 | 14,516 | 187.3% | |
Long term debt | Rs m | 4,993 | 4,189 | 119.2% | |
Total assets | Rs m | 47,778 | 29,805 | 160.3% | |
Interest coverage | x | 41.7 | 3.5 | 1,201.4% | |
Debt to equity ratio | x | 0.2 | 0.3 | 63.6% | |
Sales to assets ratio | x | 0.8 | 0.5 | 153.8% | |
Return on assets | % | 12.6 | 8.9 | 141.6% | |
Return on equity | % | 21.5 | 11.8 | 182.3% | |
Return on capital | % | 23.6 | 17.5 | 134.6% | |
Exports to sales | % | 0 | 24.8 | 0.0% | |
Imports to sales | % | 0 | 3.7 | 0.0% | |
Exports (fob) | Rs m | NA | 3,956 | 0.0% | |
Imports (cif) | Rs m | NA | 596 | 0.0% | |
Fx inflow | Rs m | 19,453 | 4,952 | 392.9% | |
Fx outflow | Rs m | 6,065 | 697 | 870.4% | |
Net fx | Rs m | 13,388 | 4,255 | 314.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 2,786 | 291.4% | |
From Investments | Rs m | -7,556 | -1,529 | 494.2% | |
From Financial Activity | Rs m | 590 | -941 | -62.7% | |
Net Cashflow | Rs m | 1,153 | 316 | 364.5% |
Indian Promoters | % | 74.1 | 61.4 | 120.7% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 3.7 | 78.4% | |
FIIs | % | 9.1 | 12.7 | 71.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 22.1 | 62.9% | |
Shareholders | 49,328 | 46,261 | 106.6% | ||
Pledged promoter(s) holding | % | 0.0 | 35.8 | - |
Compare ALEMBIC PHARMA With: NATCO PHARMA FRESENIUS KABI ONCO. FDC ABBOTT INDIA STRIDES PHARMA SCIENCE
Compare ALEMBIC PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 375 points (up 0.8%).
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More